Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ANS02 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on ANS02, a putative fourth-generation EGFR inhibitor (May 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ANS02 | ANS-02|ANS 02 | EGFR Inhibitor 4th gen 20 | Limited information is currently available on ANS02, a putative fourth-generation EGFR inhibitor (May 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07538804 | Phase Ib/II | ANS02 | A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer | Not yet recruiting | USA | 1 |